Victory Capital Management’s Fulgent Genetics FLGT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q1
Sell
-28,599
Closed -$827K 2503
2023
Q4
$827K Sell
28,599
-43,211
-60% -$1.16M ﹤0.01% 1801
2023
Q3
$1.92M Buy
71,810
+17,103
+31% +$584K ﹤0.01% 1409
2023
Q2
$2.03M Sell
54,707
-869
-2% -$30.3K ﹤0.01% 1386
2023
Q1
$1.74M Sell
55,576
-19,656
-26% -$633K ﹤0.01% 1451
2022
Q4
$2.24M Buy
75,232
+46,968
+166% +$1.68M ﹤0.01% 1396
2022
Q3
$1.08M Buy
28,264
+750
+3% +$37.6K ﹤0.01% 1703
2022
Q2
$1.5M Buy
27,514
+4,693
+21% +$258K ﹤0.01% 1565
2022
Q1
$1.26M Buy
22,821
+4,800
+27% +$316K ﹤0.01% 1685
2021
Q4
$1.81M Buy
18,021
+7,821
+77% +$687K ﹤0.01% 1587
2021
Q3
$917K Buy
10,200
+1,571
+18% +$143K ﹤0.01% 1904
2021
Q2
$796K Sell
8,629
-2,267
-21% -$181K ﹤0.01% 1973
2021
Q1
$1.05M Sell
10,896
-27,335
-71% -$2.82M ﹤0.01% 1893
2020
Q4
$1.99M Buy
+38,231
New +$1.6M ﹤0.01% 1518
2020
Q2
Sell
-3,206
Closed -$34K 2772
2020
Q1
$34K Buy
+3,206
New +$44.7K ﹤0.01% 2910
2019
Q4
Sell
-1,188
Closed -$12K 2857
2019
Q3
$12K Buy
+1,188
New +$11.3K ﹤0.01% 3193

Other funds holding FLGT

Victory Capital Management's FLGT Position: Q1 2024 in Review

Victory Capital Management sold out of Fulgent Genetics (FLGT) in Q1 2024, closing a stake of 28,599 shares — an estimated $827K sold.

Victory Capital Management first reported a position in FLGT in Q3 2019 and held it in 15 quarters. The position peaked at $2.24M in Q4 2022. 180 funds tracked by Wall St. Rank hold FLGT as of Q1 2024.

  • Victory Capital Management reported no remaining Fulgent Genetics position as of Q1 2024 after selling out during the quarter.
  • Victory Capital Management sold 28,599 Fulgent Genetics shares in Q1 2024, an estimated $827K.
  • Victory Capital Management first reported a position in Fulgent Genetics in Q3 2019 and held it in 15 quarters.
  • Victory Capital Management's Fulgent Genetics position peaked at $2.24M in Q4 2022.
  • 180 funds tracked by Wall St. Rank held Fulgent Genetics as of Q1 2024.

Based on Victory Capital Management's 13F filing for Q1 2024, filed 3 May 2024.